Press release
Key Trends Influencing the Growth of the Alzheimer's Drugs Market in 2025: Kisunla Receives Food and Drug Administration (FDA) Approval As First Amyloid Plaque-Targeting Therapy For Early Alzheimer's
Alzheimer's Drugs
What Is the Expected CAGR for the Alzheimer's Drugs Market Through 2025?
The market size of Alzheimer's drugs has notably expanded over the past few years. The forecast suggests an increase from $9.33 billion in 2024 to $10.09 billion in 2025, with a compound annual growth rate (CAGR) of 8.1%. Historical period growth factors include a surge in Alzheimer's disease instances, investments in R&D, better comprehension of disease mechanisms, global health drives, and increased public knowledge and education.
What's the Projected Size of the Global Alzheimer's Drugs Market by 2029?
In the upcoming years, the market size of Alzheimer's drugs is predicted to witness substantial growth, expanding to "$14.16 billion by 2029 with a compound annual growth rate (CAGR) of 8.8%. This anticipated growth in the forecast period is largely due to factors such as precise medicine strategies, emphasis on disease modification, identification and validation of biomarkers, patient-focused drug development, and a concentration on non-pharmacological interventions. The projected trends during this period comprise varied therapeutic approaches, digital health solutions, regenerative medicine, advancements in diagnostic technologies, application of artificial intelligence (AI) in drug advancement, and strategic partnerships and collaborations.
View the full report here:
https://www.thebusinessresearchcompany.com/report/alzheimers-drugs-global-market-report
Top Growth Drivers in the Alzheimer's Drugs Industry: What's Accelerating the Market?
The Alzheimer's drugs market is anticipated to experience significant growth due to the increasing occurrence of Alzheimer's disease. Alzheimer's disease, a neurological disorder that results in brain atrophy and cell death, worsens over time. Medications designed to manage Alzheimer's are used to alleviate memory loss, cognitive and reasoning issues, and daily life challenges. They can greatly improve the lives of patients and help them retain their independence. For example, a report by the Alzheimer's Association, a US-based nonprofit organization focused on Alzheimer's care, support, and research, indicated that in May 2024, there was a rise in the number of Americans aged 65 and older who received an Alzheimer's dementia diagnosis. The figure surged from 6.5 million in 2022 to a projected 6.9 million in 2024. Consequently, the escalating rates of Alzheimer's disease are fueling the expansion of the Alzheimer's drugs market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9040&type=smp
Which Emerging Trends Are Transforming the Alzheimer's Drugs Market in 2025?
Leading corporations in the Alzheimer's medication sector are pioneering new products like therapy targeting amyloid plaques, in order to enhance treatment alternatives and boost patient results. Therapies targeting amyloid plaques concentrate on decreasing or avoiding the build-up of amyloid-beta plaques in the brain, a key focus in Alzheimer's disease treatment. For instance, Eli Lilly and Company, an American pharmaceutical corporation, received approval for Kisunla (donanemab-azbt) from the Food and Drug Administration (FDA) in June 2024, an agency dedicated to the preservation of public health in the United States. Kisunla (donanemab-azbt) achieved a milestone as the first and only treatment specifically targeting amyloid plaques for people with early symptomatic Alzheimer's. Functioning by facilitating the body's removal of excess amyloid plaques in the brain - a known contributor to cognitive decline in Alzheimer's patients - Kisunla is given intravenously every four weeks. The initial dosage is structured as 700 mg for the first three doses and then increased to 1400 mg. The usage of Kisunla is specially designed for adults suffering from mild cognitive impairment (MCI) and the early stage of Alzheimer's dementia, given a confirmed amyloid pathology.
What Are the Main Segments in the Alzheimer's Drugs Market?
The alzheimer's drugs market covered in this report is segmented -
1) By Drugs: Donepezil, Rivastigmine, Galantamine, Memantine
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
3) By Application: Early To Moderate Stages, Moderate To Severe Stages
Subsegments:
1) By Donepezil: Oral Tablets, Oral Solution
2) By Rivastigmine: Oral Capsules, Oral Solution, Transdermal Patches
3) By Galantamine: Oral Tablets, Oral Solution, Extended-Release Capsules
4) By Memantine: Oral Tablets, Oral Solution, Extended-Release Capsules
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=9040&type=smp
Which Top Companies are Driving Growth in the Alzheimer's Drugs Market?
Major companies operating in the alzheimer's drugs market include AbbVie Inc., Daiichi Sankyo Company Limited, F Hoffmann-La Roche AG, Merck & Co Inc., Novartis AG, Biogen Inc., AstraZeneca PLC, Eisai Co Ltd., Eli Lilly and Company, H Lundbeck A/S, Pfizer Inc., Allergan PLC., Johnson & Johnson, Lupin Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Neurotrope Inc., AC Immune SA, Adamas Pharmaceuticals Inc, Alzheon Inc., Anavex Life Sciences Corp, Axsome Therapeutics Inc., Cassava Sciences Inc., Cognition Therapeutics Inc., Cortexyme Inc., Denali Therapeutics Inc, EIP Pharma Inc., Enlivex Therapeutics Ltd., FORUM Pharmaceuticals Inc., Genentech Inc., Green Valley Pharmaceuticals LLC, Intra-Cellular Therapies Inc., Karuna Therapeutics Inc., Neurim Pharmaceuticals Ltd
Which Regions Will Dominate the Alzheimer's Drugs Market Through 2029?
North Americawas the largest region in the Alzheimer's drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the Alzheimer's drugs market during the forecast period. The regions covered in the Alzheimer's drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9040
This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795,
Asia +44 7882 955267 & +91 8897263534,
Europe +44 7882 955267
Email:saumyas@tbrc.info
The Business Research Company -www.thebusinessresearchcompany.com
Follow Us On:
LinkedIn:https://in.linkedin.com/company/the-business-research-company
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Key Trends Influencing the Growth of the Alzheimer's Drugs Market in 2025: Kisunla Receives Food and Drug Administration (FDA) Approval As First Amyloid Plaque-Targeting Therapy For Early Alzheimer's here
News-ID: 4180265 • Views: …
More Releases from The Business Research Company
Key Drivers Reshaping the Purvalanol A (CDK Inhibitor) Market: Increasing Preval …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Purvalanol A (CDK Inhibitor) Market Size Growth Forecast: What to Expect by 2025?
The market size for purvalanol A (CDK inhibitor) has witnessed a substantial expansion in the past few years. It is projected to escalate from $0.58 billion in 2024 to $0.64 billion in 2025, with a compound…
Growing Emphasis On Personalized Medicine Driving The Market Due To Advances In …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Polygenic Risk Score Services Market Size Growth Forecast: What to Expect by 2025?
The market size for polygenic risk score services has seen considerable growth in recent years. Anticipated to increase from $1.24 billion in 2024 to $1.45 billion in 2025, it projects a compound annual growth rate (CAGR)…
Future of the Global Pharmaceutical Unit-Dose Packaging Market: Trends, Innovati …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Pharmaceutical Unit-Dose Packaging Market Size Growth Forecast: What to Expect by 2025?
The market size of the pharmaceutical unit-dose packaging industry has experienced quick expansion in the recent past. The market, valued at $48.78 billion in 2024, is projected to rise to $54.50 billion in 2025, reflecting a compound…
Personal Care Product Testing Market Poised to Hit $10.37 Billion by 2029 with A …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Personal Care Product Testing Market Size Growth Forecast: What to Expect by 2025?
In the past few years, the market size for personal care product testing has seen robust growth. It's projected to increase from $7.28 billion in 2024 to $7.84 billion in 2025, with a compound annual growth…
More Releases for Alzheimer
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…
